| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $132.0M | -39.3% |
| SG&A Expense | $44.3M | -30.8% |
| Operating Income | -$250.3M | +8.2% |
| Income Tax | $0 | — |
| Net Income | -$244.2M | +8.5% |
| EPS (Basic) | -$0.96 | +17.2% |
| EPS (Diluted) | -$0.96 | +17.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $71.9M | -43.7% |
| Short-term Investments | $66.5M | +166.8% |
| Current Assets | $148.7M | -7.5% |
| Total Assets | $416.9M | -16.8% |
| Current Liabilities | $78.7M | +73.3% |
| Total Liabilities | $256.0M | +2.2% |
| Stockholders' Equity | $160.9M | -35.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$143.8M | +35.5% |
| Capital Expenditures | $938K | -97.2% |
| Investing Cash Flow | -$40.2M | -330.6% |
| Financing Cash Flow | $128.7M | -35.6% |
| Free Cash Flow | -$144.8M | +43.6% |